Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BY-NC 4.0The European Journal of Public Health

Characteristics of cisgender women and transgender people in harm reduction programs in Barcelona

Abstract

Background: Cisgender women and transgender people with problematic drug use face greater barriers to accessing drug services and poorer health outcomes than cisgender men. These inequalities are particularly relevant in harm reduction (HR) programs, which aim to reduce adverse consequences of drug use but have traditionally been designed from an androcentric perspective, often failing to address the specific needs of these populations. A better understanding of their sociodemographic characteristics, health status and patterns of drug use is key to inform gender‑responsive HR interventions and reduce existing inequalities in access and care.

Methods: A descriptive cross-sectional study analysed sociodemographic and health characteristics of cisgender women and transgender people accessing at least one HR program in Barcelona who completed a questionnaire in 2025. Drug use patterns were examined using registered inhaled or injected consumption episodes from Drug Consumption Rooms (DCR) in 2025. Data were obtained from the Harm Reduction Registry of the Public Health Agency of Catalonia.

Results: The questionnaire sample included 441 cisgender women and 13 transgender people. Most were aged 30–49 years (67%), 58% were born in Spain, and 60% were experiencing homelessness. Approximately 35% reported being in treatment for drug use, and 12% self-reported HIV and/or HCV. Among DCR users, 245 cisgender women accounted for 11,470 consumption episodes, mainly involving methamphetamine (46%), cocaine (25%) and heroin (18%). Among seven transgender users, 245 episodes were recorded, 95% involving methamphetamine.

Conclusions: Cisgender women and transgender people using HR programs experience marked social and health vulnerability and high-risk patterns of drug use, underscoring the need for gender-responsive HR strategies to reduce barriers to access and drug-related health risks.

Key messages: • Cisgender women and transgender people in harm reduction programs face high social and health vulnerability, highlighting the need for gender‑responsive strategies to reduce barriers to care.

• Cisgender women and transgender people remain underrepresented in HR programs and experience high homelessness, infectious disease exposure and intense stimulant use, requiring tailored responses.

Related

  1. Somatic symptoms in cisgender men, transgender men, and gender-diverse individuals assigned male at birth: a Swiss Nationwide Study
    Marietta Lieb, Johanna Jedamzik, Nora M. Laskowski +2
    Scientific ReportsPeer-reviewedCC BY 4.0Full textPsychiatry & mental healthCrossref
  2. Barriers and facilitators to implementing national sodium reduction programs in rural China: a qualitative study
    Shuangjie Peng, Yuze Xin, Jianwei Xu +14
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
  3. Participant Characteristics Associated With Loneliness Reduction During a Digital Social Robot Intervention Among Older Adults Living Alone in Japan: Secondary Analysis of a Randomized Controlled Trial
    Hiroshi Murayama, Mai Takase
    Journal of Medical Internet ResearchPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  4. Characteristics of junior residents choosing alternative career pathways without entering traditional specialty residency programs: An exploratory descriptive study
    Koshi Ota, Kanna Ota
    SAGE Open MedicinePeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCEurope PMC
  5. Clinical and anamnestic characteristics of infertile patients with ovarian endometriomas in assisted reproductive technology programs
    A.V. Volyanyuk, I.Z. Gladchuk, N.M. Rozhkovska +2
    Репродуктивная эндокринологияPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsDOAJ
BibTeX
@article{garrido2026characteristics,
  title = {{Characteristics of cisgender women and transgender people in harm reduction programs in Barcelona}},
  author = {A Garrido and D Ruiz-Muñoz and M Gotsens and L Palència and V Puig-Barrachina and M Ferrer-Fons and MG Barbaglia and M Bartroli},
  journal = {The European Journal of Public Health},
  year = {2026},
  month = oct,
  doi = {10.1093/eurpub/ckag169.1575},
  url = {https://doi.org/10.1093/eurpub/ckag169.1575},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Characteristics of cisgender women and transgender people in harm reduction programs in Barcelona
AU  - A Garrido
AU  - D Ruiz-Muñoz
AU  - M Gotsens
AU  - L Palència
AU  - V Puig-Barrachina
AU  - M Ferrer-Fons
AU  - MG Barbaglia
AU  - M Bartroli
PY  - 2026
DA  - 2026/10/01
JO  - The European Journal of Public Health
DO  - 10.1093/eurpub/ckag169.1575
UR  - https://doi.org/10.1093/eurpub/ckag169.1575
AB  - Background: Cisgender women and transgender people with problematic drug use face greater barriers to accessing drug services and poorer health outcomes than cisgender men. These inequalities are particularly relevant in harm reduction (HR) programs, which aim to reduce adverse consequences of drug use but have traditionally been designed from an androcentric perspective, often failing to address the specific needs of these populations. A better understanding of their sociodemographic characteristics, health status and patterns of drug use is key to inform gender‑responsive HR interventions and reduce existing inequalities in access and care.  Methods: A descriptive cross-sectional study analysed sociodemographic and health characteristics of cisgender women and transgender people accessing at least one HR program in Barcelona who completed a questionnaire in 2025. Drug use patterns were examined using registered inhaled or injected consumption episodes from Drug Consumption Rooms (DCR) in 2025. Data were obtained from the Harm Reduction Registry of the Public Health Agency of Catalonia.  Results: The questionnaire sample included 441 cisgender women and 13 transgender people. Most were aged 30–49 years (67%), 58% were born in Spain, and 60% were experiencing homelessness. Approximately 35% reported being in treatment for drug use, and 12% self-reported HIV and/or HCV. Among DCR users, 245 cisgender women accounted for 11,470 consumption episodes, mainly involving methamphetamine (46%), cocaine (25%) and heroin (18%). Among seven transgender users, 245 episodes were recorded, 95% involving methamphetamine.  Conclusions: Cisgender women and transgender people using HR programs experience marked social and health vulnerability and high-risk patterns of drug use, underscoring the need for gender-responsive HR strategies to reduce barriers to access and drug-related health risks.  Key messages: • Cisgender women and transgender people in harm reduction programs face high social and health vulnerability, highlighting the need for gender‑responsive strategies to reduce barriers to care.  • Cisgender women and transgender people remain underrepresented in HR programs and experience high homelessness, infectious disease exposure and intense stimulant use, requiring tailored responses.
SN  - 1101-1262
SN  - 1464-360X
ER  -